Goldman Sachs Resumes Estee Lauder (EL) at Buy, Citing Secular Trends
Tweet
Share
E-mailGet Alerts EL Hot Sheet
Price: $86.10 -1.4%
Rating Summary:
20 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
20 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs resumes coverage on Estee Lauder (NYSE: EL) with a Buy. PT $77.00.
The firm comments, "We recommend investors buy pure-play EL to gain focused exposure to the most powerful secular trends in HPC and benefit by compounding returns on best-in-class mid-teens EPS growth"
Goldman notes the company benefits from direct exposure to two secular trends: (1) emerging market growth with outsized potential in Asia where both penetration and premiumization opportunities exceed other Staples categories; and (2) above-average DM growth where pursuit of the fountain of youth by an aging consumer drives higher trade-in and trade-up opportunities.
For an analyst ratings summary and ratings history on Estee Lauder click here. For more ratings news on Estee Lauder click here.
Shares of Estee Lauder closed at $59.91 yesterday.
The firm comments, "We recommend investors buy pure-play EL to gain focused exposure to the most powerful secular trends in HPC and benefit by compounding returns on best-in-class mid-teens EPS growth"
Goldman notes the company benefits from direct exposure to two secular trends: (1) emerging market growth with outsized potential in Asia where both penetration and premiumization opportunities exceed other Staples categories; and (2) above-average DM growth where pursuit of the fountain of youth by an aging consumer drives higher trade-in and trade-up opportunities.
For an analyst ratings summary and ratings history on Estee Lauder click here. For more ratings news on Estee Lauder click here.
Shares of Estee Lauder closed at $59.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- The Estée Lauder Companies and University of Leeds Partner to Advance the Future of Complexion Shade Matching
- Leerink Starts Ligand Pharma (LGND) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
